Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

Vaccine

Volumn 25, Issue 17, 2007, Pages 3277-3283

  Dorrell, Lucy ^a   Williams, Patricia ^a   Suttill, Annie ^a   Brown, Denise ^a   Roberts, Joanna ^a   Conlon, Christopher ^a   Hanke, Tomáš ^a   McMichael, Andrew ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Clinical study; HIV 1; Modified vaccinia virus Ankara

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS VECTOR;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIGEN EXPRESSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILE DUCT DILATATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DNA VECTOR; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GALLSTONE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION RISK; INJECTION SITE PAIN; MALE; MODIFIED VACCINIA VIRUS ANKARA; NAUSEA; POXVIRUS; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DEFECT; SKIN DISCOLORATION; SKIN DISCOMFORT; SKIN INDURATION; SKIN ULCER; SORE THROAT; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; VACCINIA VIRUS; VIREMIA; VIRUS ATTENUATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE PRODUCTS, GAG; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; VIRAL PROTEINS;

EID: 34047189908     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.005     Document Type: Article

References (36)

1. Dorrell L. Therapeutic immunization strategies for the control of HIV-1. Expert Rev Vaccines 4 4 (2005) 513-520
2. Bejon P., Peshu N., Gilbert S.C., Lowe B.S., Molyneux C.S., Forsdyke J., et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 42 8 (2006) 1102-1110
3. McShane H., Pathan A., Sander C., Keating S., Gilbert S., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 11 (2004) 1240-1244
4. Mayr A., Stickl H., Muller H., Danner K., and Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zbl Bakt Hyg I Abt Orig B 167 (1978) 375-390
5. Blanchard T., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for uses as a human vaccine. J Gen Virol 79 (1998) 1159-1167
6. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 (1998) 347-352
7. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. PNAS 89 22 (1992) 10847-10851
8. Drillien R., Spehner D., and Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol 85 8 (2004) 2167-2175
9. Hanke T., McMichael A.J., Samuel R.V., Powell L.A.J., McLoughlin L., Crome S.J., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21 1-2 (2002) 108-114
10. Stittelaar K., Kuiken T., de Swart R., van Amerongen G., Vos H., Niesters H., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 (2001) 3700-3709
11. Hanke T., McMichael A.J., Dennis M.J., Sharpe S.A., Powell L.A.J., McLoughlin L., et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23 12 (2005) 1507-1514
12. McConkey S., Reece W., Moorthy V., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 9 6 (2003) 729-735
13. Moorthy V., Imoukhuede E., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1 (2004) e33
14. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 1 (2003) 21-29
15. Harrer E., Bäuerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antiviral Ther 10 (2005) 285-300
16. Hanke T., and McMichael A. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6 (2000) 951-955
17. Dorrell L., Yang H., Ondondo B., Dong T., de Gleria K., Suttill A., et al. Expansion and diversification of virus-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J Virol 80 10 (2006) 4705-4716
18. Ondondo B., Yang H., Dong T., di Gleria K., Suttill A., Conlon C., et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36 10 (2006) 2585-2594
19. Dorrell L., Yang H., Iversen A., Conlon C., Suttill A., Lancaster M., et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/polyepitope DNA vaccine. AIDS 19 (2005) 1321-1323
20. Moorthy V., Imoukhuede E., Keating S., Pinder M., Webster D., Skinner M., et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis. 189 12 (2004) 2213-2219
21. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 4 (2006) 417-425
22. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 (1998) 397-402
23. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 15 (2006) 3026-3034
24. Redfield R., Wright D., James W., Jones T., Brown C., and Burke D. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316 (1987) 673-676
25. Tasker S., Schnepf G., Lim M., Caraviello H., Armstrong A., Bavaro M., et al. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis 38 (2004) 1320-1322
26. Florence E., Lundgren J., Dreezen C., Fisher M., Kirk O., Blaxhult A., et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine 4 3 (2003) 255-262
27. Hirsch H., Kaufmann G., Sendi P., and Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 38 (2004) 1159-1166
28. Sutherland R., Yang H., Scriba T., Ondondo B., Robinson N., Conlon C., et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 20 (2006) 821-829
29. Stanley S.K., Ostrowski M.A., Justement J.S., Gantt K., Hedayati S., Mannix M., et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 334 19 (1996) 1222-1229
30. Staprans S., Hamilton B., Follansbee S., Elbeik T., Barbosa P., Grant R., et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 182 6 (1995) 1727-1737
31. Fuller J., Craven D., Steger K., Cox N., Heeren T., and Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 28 3 (1999) 541-547
32. Tasker S.A., Treanor J.J., Paxton W.B., and Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 131 6 (1999) 430-433
33. Janoff E., Tasker S., Stevenson M., Rubins J., O'Brien J., Utz G., et al. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. AIDS Res Hum Retroviruses 15 9 (1999) 837-845
34. Levy Y., Gahery-Segard H., Durier C., Lascaux A., Goujard C., Meiffredy V., et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19 3 (2005) 279-286
35. Tubiana R., Carcelain G., Vray M., Gourlain K., Dalban C., Chermak A., et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23 34 (2005) 4292-4301
36. Smith C.L., Mirza F., Pasquetto V., Tscharke D.C., Palmowski M.J., Dunbar P.R., et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175 12 (2005) 8431-8437